Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease
- Conditions
- Alzheimer Disease
- Interventions
- Other: Multi-sensory supportive care
- Registration Number
- NCT01819714
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Brief Summary
The main objective of this study is to evaluate the effect of 3 months of "Snoezelen-type" multi-sensory care sessions on NeuroPsychiatric Inventory Questionnaire (NPI-Q) scores for patients with Alzheimer's-type neurodegenerative disease.
- Detailed Description
The secondary objectives of this study are to study the following elements in relationship to the implementation of a "Snoezelen-type" multi-sensory care strategy for patients with Alzheimer's-type neurodegenerative disease:
A. to evaluate the effects on NPI-Q scores at 1 month, 6 months and 12 months .
B. evaluate the effects on quality of life (questionnaire QOL-AD) at 0 and 12 months.
C. assess changes in the "aggressive behavior" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire over 0, 1, 3, 6 and 12 months.
D. assess changes in drug consumption (anxiolytics, antidepressants, hypnotics, neuroleptics)over the study period
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
- The patient's legal representative must have given his/her informed and signed consent (or the patient if he/she is judged competent)
- The patient must be insured or beneficiary of a health insurance plan
- Alzheimer's-type neurodegenerative pathology
- The patient has been living in the participating center for > 2 months
- The patient's legal representative refuses to sign the consent (or the patient if he/she is judged competent)
- It is impossible to correctly inform the patient's legal representative
- The patient has already has Snoezelen-therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Study population Multi-sensory supportive care Patients hospitalized at the Serre-Cavalier centre and who have Alzheimer's-type neurodegenerative disease (see inclusion criteria).
- Primary Outcome Measures
Name Time Method Change from baseline in NPI-Q scores 3 months
- Secondary Outcome Measures
Name Time Method Change from baseline in NPI-Q scores 12 months Change in drug consumption from baseline 12 months Change from baseline in the "aggressive behavior" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire 12 months Change from baseline in the Quality-of-life-Alzheimer's Disease questionnaire (QOL-AD) 12 months
Trial Locations
- Locations (1)
CHU de Nîmes - Centre de Gérontologie de Serre Cavalier
🇫🇷Nîmes, France